Earnings ·
biote Corp. reported second quarter 2026 financial results on August 5, 2026, revealing a net loss of $7.4 million and…
BTMDbiote Corp.
biote Corp. reported second quarter 2026 financial results on August 5, 2026, revealing a net loss of $7.4 million and diluted loss per share of $0.23, compared to net income of $3.9 million in the prior year period. Total revenue declined 9.5% to $44.2 million, driven by a 13.9% drop in procedure revenue to $30.3 million due to a voluntary product recall initiated in January 2026 involving hormone pellets from supplier Asteria Health. Gross profit margin contracted to 65.4% from 71.6%, while Adjusted EBITDA fell to $5.6 million from $15.2 million. The company revised its full-year guidance, projecting revenue above $175 million and Adjusted EBITDA above $25 million, noting that procedure revenue is expected to improve sequentially but remain below year-over-year levels due to the recall disruption. biote Corp. operates in the hormone optimization and healthy aging solutions industry.